Shares of Healthcare Global Enterprises (HCG) declined 1.95% to Rs 573.30 in early trade on February 25 after the company announced the terms of its proposed rights issue.
The board, at its meeting held on February 24, approved the issuance of fully paid-up equity shares of face value Rs 10 each through a rights offering aggregating to Rs 424.68 crore, assuming full subscription.
Key details of the rights issue
- Total shares offered: 82,94,566 Rights Equity Shares
- Issue size: Rs 424.68 crore
- Rights issue price: Rs 512 per share (including a premium of Rs 502)
- Rights entitlement ratio: 1 Rights Equity Share for every 17 fully paid-up equity shares held
- Record date: March 2, 2026
- Issue opening date: March 11, 2026
- Issue closing date: March 25, 2026
- Proposed listing date: April 1, 2026
The rights issue price of Rs 512 per share is at a discount to the current market price of Rs 573.30, which may have led to the mild pressure on the stock.
How the rights entitlement works
Eligible shareholders holding equity shares as of the record date will receive Rights Entitlements (REs), which will be credited to their demat accounts under ISIN: INE075I20017 prior to the issue opening date.
Shareholders can:
- Subscribe to their entitled shares
- Apply for additional shares
- Renounce the rights partially or fully
The company has made arrangements with NSDL and CDSL for crediting REs into the demat accounts of eligible shareholders.
What investors are factoring in
Rights issues often lead to short-term volatility due to:
- Dilution impact
- Pricing discount to market price
- Capital structure changes
However, such capital raises can also strengthen the balance sheet depending on the intended use of proceeds.
Investors will now track subscription levels and management commentary on fund utilisation to assess the medium-term impact.
Disclaimer: This article is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.